latest update:
[TrialBase DB]

trial summary · NCT07224763

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)

Trial record from the TrialBase DB dataset, status RECRUITING, condition ESRD (End-Stage Renal Disease), sponsored by United Therapeutics. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07224763phase PHASE1/PHASE2enrollment 50start 2026-11

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant or for 52 weeks following nephrectomy, if required.

Source record: https://clinicaltrials.gov/study/NCT07224763

Facts

registry idNCT07224763
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionESRD (End-Stage Renal Disease)
sponsorUnited Therapeutics
sponsor classINDUSTRY
enrollment50
start date2026-11
primary completion2029-11
completionnot reported
results postednot reported

Conditions

  • ESRD (End-Stage Renal Disease)
  • Kidney Transplantation
  • Xenotransplantation

Interventions

  • GGTA1 KO Thymokidney

Countries

  • United States

Intervention types: BIOLOGICAL

Work with this record